title: Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings.
abstract: BACKGROUND
  This study used case reports to review the role of systemic chemotherapy in oligometastatic colorectal cancer (CRC) and to suggest ways to integrate clinical research findings into the interdisciplinary management of this potentially curable subset of patients.
  
  
  METHODS
  This educational review discusses the role of chemotherapy in the management of oligometastatic metastatic CRC.
  
  
  RESULTS
  In initially resectable oligometastatic CRC, the goal of chemotherapy is to eradicate micrometastatic disease. Perioperative 5-fluorouracil and oxaliplatin together with surgical resection can result in 5-year survival rates as high as 57 %. With the development of increasingly successful chemotherapy regimens, attention is being paid to chemotherapy used to convert patients with initially unresectable metastasis to patients with a chance of surgical cure. The choice of chemotherapy regimen requires consideration of the goals for therapy and assessment of both tumor- and patient-specific factors.
  
  
  CONCLUSIONS
  This report discusses the choice and timing of chemotherapy in patients with initially resectable and borderline resectable metastatic CRC. Coordinated multidisciplinary care of such patients can optimize survival outcomes and result in cure for patients with this otherwise lethal disease.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Semrad
authors.affiliation: Kaiser Permanente Medical Group, Sacramento, CA, USA.
authors.forename: Ana Rodriguez
authors.initials: AR
authors.lastname: Fahrni
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
authors.forename: I-Yeh
authors.initials: IY
authors.lastname: Gong
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. vijay.khatri@ucdmc.ucdavis.edu.
authors.forename: Vijay P
authors.initials: VP
authors.lastname: Khatri
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D019468:Disease Management; D019317:Evidence-Based Medicine; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate